Taking 500 mg cephalexin twice daily is as effective as taking it four times daily for treating urinary tract infections in ...

Over the past three years, there has been a sudden surge in drug abuse in Kerala, sparking widespread concern. In March, the Kerala High Court warned of the “poisonous fangs of the drug mafia ...

MG Motor India is set to ace up its line-up with the premium MG Select dealerships coming in place. The carmaker took the veils of a few new vehicles at Bharat Mobility Global Expo 2025.

The Long Range comes with a 64kWh battery and 288 miles of range, while the Extended Range edition has a 77kWh battery for up to 329 miles of range. Finally, MG also offers an Xpower edition with dual ...

MG has played an important role at the entry-level end of Australia's new car market. Compact cars like the MG ZS SUV and MG 3 city car were often lauded for their affordable price and value-for ...

In a significant drug bust, over 100 pounds of methamphetamine were seized during a traffic stop conducted by the West Tennessee Drug Task Force on I-40 late Tuesday night. The incident took place ...

JSW MG Motor India has launched the MG Comet EV 2025. While the electric car can be bought at a starting price of Rs 7 lakh (ex-showroom), the battery-as-a-service (BaaS) model allows you to have it ...

IT之家3 月 19 日消息，上汽 MG 名爵汽车宣布旗下“2025 年首款新车”正式命名 MG4 EV，此前官方透露该车为“新能源大 5 座 SUV”。 参考该公司发布的海报，这款 SUV 车型整体呈现掀背式外观，车头采用封闭式设计，并配备有不规则造型的大灯。车身采用常规造型的 ...

Your browser does not support the audio element. The MG Comet line-up has been updated for 2025 with a few feature upgrades, except for the entry-level Executive ...

The MG Comet EV 2025, presented by JSW MG Motor India, sets a new standard for electric city cars in India by combining enhanced convenience, comfort, and safety. With a starting price of Rs 4.99 ...

A new study has discovered what researchers say is the first drug to fully reproduce the effects of physical stroke rehabilitation in model mice, following from human studies. A new study by UCLA ...

The drug, povorcitinib, accomplished its goal of reducing symptoms for a skin disease, but at a lower rate than previous trials. The drugmaker was the biggest decliner in the S&P 500 on Monday.